The Enzolytics Inc (OTCMKTS:ENZC) stock had been one of the more notable gainers some weeks back when it hit its peak. However, things have been quite different in recent times and since hitting its peak, the Enzolytics stock has gone down substantially.

In this regard, it should also be noted by investors that the Enzolytics stock has also displayed considerable volatility in recent times. While that may be true, there was a significant new development earlier this month that might have far-reaching ramifications for the company and its stock. The drug development company made an announcement about the monoclonal antibodies that it has been developing.

In a significant development, the company announced that the monoclonal antibodies, which are meant for targeting certain sites on the coronavirus, can also work on some of the other variants. The variants are the new strains of the coronavirus from Brazil, the United Kingdom, and South Africa.

This is a particularly important development for Enzolytics considering the fact that these strains of the coronavirus have been classified as ‘variants of concern’ by the Center for Disease Control. These strains have resulted in a much higher degree of COVID 19 transmission and on top of that patients infected with these variants have also generally displayed more severe symptoms.

These are the variants of the coronavirus that have been responsible for the spike in cases in the United States. As much as 26% of all the infections reported in the United States have been found to have been caused by the United Kingdom variant of the virus. Hence, it is clear to see the findings from the study into the monoclonal antibodies could prove to be a vital breakthrough for Enzolytics.

At this point, Enzolytics is looking to develop fully human monoclonal antibodies that can then be used to tackle the different variants of the coronavirus. Despite the recent situation with the Enzolytics stock, investors could consider tracking the stock.

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.